Advertisement

Clinical and Translational Oncology

, Volume 12, Issue 3, pp 188–210 | Cite as

Colorectal cancer OncoGuia

  • Paula Manchon WalshEmail author
  • Josep M. Borràs
  • Tàrsila Ferro
  • Josep Alfons Espinàs
  • Colorectal Cancer OncoGuia Group
Special Article

Keywords

Colorectal Cancer Rectal Cancer Clin Oncol Total Mesorectal Excision Peritoneal Carcinomatosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Manchon Walsh P, Borràs JM (2009) Clinical practice guidelines for cancer care: what are they for? Clin Transl Oncol 11:775–776PubMedCrossRefGoogle Scholar
  2. 2.
    National Institute for Health and Clinical Excellence (2007) The guidelines manual. National Institute for Health and Clinical Excellence, London, April. Available at www.nice.org.uk
  3. 3.
    Borràs JM, Pareja L, Peris M, Espinàs JA (2008) Análisis de la incidencia, la supervivencia y la mortalidad según las principales localizaciones tumorales, 1985–2019: cáncer colorrectal. Med Clin Monogr (Barc) 9:58–62CrossRefGoogle Scholar
  4. 4.
    Fielding LP, Arsenault PA, Chapuis PH et al (1991) Clinicopathological staging for colorectal cancer: an International Documentation System (IDS) and an International Comprehensive Anatomical Terminology (ICAT). J Gastroenterol Hepatol 6:325–344PubMedCrossRefGoogle Scholar
  5. 5.
    Bisset IP, Chau KY, Hill GL (2000) Extrafascial excision of the rectum: surgical anatomy of the fascia propria. Dis Colon Rectum 43:903–910PubMedCrossRefGoogle Scholar
  6. 6.
    Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP (2000) American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 88:1739–1757PubMedCrossRefGoogle Scholar
  7. 7.
    Wong JH, Severino R, Honnebier MB et al (1999) Number of nodes examined and staging accuracy in colorectal carcinoma. J Clin Oncol 17:2896–2900PubMedGoogle Scholar
  8. 8.
    Le Voyer TE, Sigurdson ER, Hanlon AL et al (2003) Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 21:2912–2919PubMedCrossRefGoogle Scholar
  9. 9.
    Biondo S, Kreisler E, Millan M et al (2008) Differences in patient postoperative and long-term outcomes between obstructive and perforated colonic cancer. Am J Surg 195:427–432PubMedCrossRefGoogle Scholar
  10. 10.
    (2008) OncoGuia del consell i assessorament genètics en el càncer hereditari. Versió breu per a l’aplicació en la pràctica clínica. Agència d’Avaluació de Tecnología i Recerca Mèdiques CatSalut Departament de Salut Generalitat de Catalunya, Barcelona, Juny 2006 (OG01/2006)Google Scholar
  11. 11.
    Leaper M, Johnston MJ, Barclay M et al (2004) Reasons for failure to diagnose colorectal carcinoma at colonoscopy. Endoscopy 36:499–503PubMedCrossRefGoogle Scholar
  12. 12.
    Bressler B, Paszat LF, Vinden C et al (2004) Colonoscopic miss rates for right-sided colon cancer: a population-based analysis. Gastroenterology 127:452–456PubMedCrossRefGoogle Scholar
  13. 13.
    Rex DK, Bond JH, Winawer S et al (2002) Quality in the technical performance of colonoscopy and the continuous quality improvement process for colonoscopy: recommendations of the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol 97:1296–1308PubMedCrossRefGoogle Scholar
  14. 14.
    Su MY, Hsu CM, Ho YP et al (2006) Comparative study of conventional colonoscopy, chromoendoscopy, and narrow-band imaging systems in differential diagnosis of neoplastic and nonneoplastic colonic polyps. Am J Gastroenterol 101:2711–2716PubMedCrossRefGoogle Scholar
  15. 15.
    Chiu HM, Chang CY, Chen CC et al (2007) A prospective comparative study of narrow-band imaging, chromoendoscopy, and conventional colonoscopy in the diagnosis of colorectal neoplasia. Gut 56:373–379PubMedCrossRefGoogle Scholar
  16. 16.
    Rex DK, Helbig CC (2007) High yields of small and flat adenomas with high-definition colonoscopes using either white light or narrow band imaging. Gastroenterology 133:42–47PubMedCrossRefGoogle Scholar
  17. 17.
    Adler A, Pohl H, Papanikolaou IS et al (2008) A prospective randomised study on narrow-band imaging versus conventional colonoscopy for adenoma detection: does narrow-band imaging induce a learning effect? Gut 57:59–64PubMedCrossRefGoogle Scholar
  18. 18.
    Rosman AS, Korsten MA (2007) Meta-analysis comparing CT colonography, air contrast barium enema, and colonoscopy. Am J Med 120:203–210PubMedCrossRefGoogle Scholar
  19. 19.
    Winawer SJ, Zauber AG, Fletcher RH et al (2006) Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology 130:1872–1885PubMedCrossRefGoogle Scholar
  20. 20.
    Winawer SJ, Zauber AG, Ho MN et al (1993) Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 329:1977–1981PubMedCrossRefGoogle Scholar
  21. 21.
    Thiis-Evensen E, Hoff GS, Sauar J et al (1999) Population-based surveillance by colonoscopy: effect on the incidence of colorectal cancer. Telemark Polyp Study I. Scand J Gastroenterol 34: 414–420PubMedCrossRefGoogle Scholar
  22. 22.
    Cooper HS, Deppisch LM, Gourley WK et al (1995) Endoscopically removed malignant colorectal polyps: clinicopathologic correlations. Gastroenterology 108:1657–1665PubMedCrossRefGoogle Scholar
  23. 23.
    Engstrom PF, Arnoletti JP, Benson AB et al (2007) Fox Chase Cancer Center Partners. Colon cancer. J Natl Compr Canc Netw 5:884–925PubMedGoogle Scholar
  24. 24.
    Van Cutsem EJ, Oliveira J (2008) Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19[Suppl 2]:ii33–ii34PubMedCrossRefGoogle Scholar
  25. 25.
    Breitenstein S, Rickenbacher A, Berdajs D et al (2007) Systematic evaluation of surgical strategies for acute malignant left-sided colonic obstruction. Br J Surg 94:1451–1460PubMedCrossRefGoogle Scholar
  26. 26.
    Lee YM, Law WL, Chu KW, Poon RT (2001) Emergency surgery for obstructing colorectal cancers: a comparison between right-sided and left-sided lesions. J Am Coll Surg 192:719–725PubMedCrossRefGoogle Scholar
  27. 27.
    Jackson TD, Kaplan GG, Arena G et al (2007) Laparoscopic versus open resection for colorectal cancer: a metaanalysis of oncologic outcomes. J Am Coll Surg 204:439–446PubMedCrossRefGoogle Scholar
  28. 28.
    Noel JK, Fahrbach K, Estok R et al (2007) Minimally invasive colorectal resection outcomes: short-term comparison with open procedures. J Am Coll Surg 204:291–307PubMedCrossRefGoogle Scholar
  29. 29.
    Lacy AM, Garcia-Valdecasas JC, Delgado S et al (2002) Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet 359:2224–2229PubMedCrossRefGoogle Scholar
  30. 30.
    Breukink S, Pierie J, Wiggers T (2006) Laparoscopic versus open total mesorectal excision for rectal cancer. Cochrane Database Syst Rev (4):CD005200PubMedGoogle Scholar
  31. 31.
    Color II Study Group. COLOR II (2009) A randomized clinical trial comparing laparoscopic and open surgery for rectal cancer. Dan Med Bull 56:89–91Google Scholar
  32. 32.
    Ruiz-Rabelo JF, Monjero Ares I, Torregrosa-Gallud A et al (2006) [Fast-track multimodal rehabilitation programs in laparoscopic colorectal surgery]. Cir Esp 80:361–368PubMedCrossRefGoogle Scholar
  33. 33.
    Wind J, Hofl J, and Preckel B et al (2006) Perioperative strategy in colonic surgery; LAparoscopy and/or FAst track multimodal management versus standard care (LAFA trial). BMC Surg 6:16PubMedCrossRefGoogle Scholar
  34. 34.
    Biondo S, Marti-Rague J, Kreisler E et al (2005) A prospective study of outcomes of emergency and elective surgeries for complicated colonic cancer. Am J Surg 189:377–383PubMedCrossRefGoogle Scholar
  35. 35.
    McArdle CS, McMillan DC, Hole DJ (2006) The impact of blood loss, obstruction and perforation on survival in patients undergoing curative resection for colon cancer. Br J Surg 93:483–488PubMedCrossRefGoogle Scholar
  36. 36.
    Biondo S, Kreisler E, Millan M et al (2007) [Long-term results of emergency surgery for colon cancer compared with elective surgery]. Cir Esp 82:89–98PubMedCrossRefGoogle Scholar
  37. 37.
    Goyal A, Schein M (2001) Current practices in left-sided colonic emergencies: a survey of US gastrointestinal surgeons. Dig Surg 18:399–402PubMedCrossRefGoogle Scholar
  38. 38.
    Martinez-Santos C, Lobato RF, Fradejas JM et al (2002) Self-expandable stent before elective surgery vs. emergency surgery for the treatment of malignant colorectal obstructions: comparison of primary anastomosis and morbidity rates. Dis Colon Rectum 45:401–406PubMedCrossRefGoogle Scholar
  39. 39.
    Biondo S, Pares D, Frago R et al (2004) Large bowel obstruction: predictive factors for postoperative mortality. Dis Colon Rectum 47:1889–1897PubMedCrossRefGoogle Scholar
  40. 40.
    Baron TH (2005) Colonic stenting: technique, technology, and outcomes for malignant and benign disease. Gastrointest Endosc Clin N Am 15:757–771PubMedCrossRefGoogle Scholar
  41. 41.
    Small AJ, Baron TH (2008) Comparison of Wallstent and Ultraflex stents for palliation of malignant left-sided colon obstruction: a retrospective, case-matched analysis. Gastrointest Endosc 67:478–488PubMedCrossRefGoogle Scholar
  42. 42.
    Chau I, Norman AR, Cunningham D et al (2005) A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 16: 549–557PubMedCrossRefGoogle Scholar
  43. 43.
    Goldberg RM, Tabah-Fisch I, Bleiberg H et al (2006) Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24:4085–4091PubMedCrossRefGoogle Scholar
  44. 44.
    Haller DG, Catalano PJ, Macdonald JS et al (2005) Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 23:8671–8678PubMedCrossRefGoogle Scholar
  45. 45.
    De Placido S, Lopez M, Carlomagno C et al (2005) Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study. Br J Cancer 93:896–904PubMedCrossRefGoogle Scholar
  46. 46.
    Tyagi P (2005) Adjuvant irinotecan regimens in combination with infusional 5-fluorouracil/leucovorin fail to improve outcomes in surgically resected colorectal cancer. Clin Colorectal Cancer 5:86–88PubMedGoogle Scholar
  47. 47.
    Mosolits S, Nilsson B, Mellstedt H (2005) Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials. Exp Rev Vaccines 4:329–350CrossRefGoogle Scholar
  48. 48.
    Nordlinger B, Rougier P, Arnaud JP et al (2005) Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II–III colorectal cancer: a multicentre randomised controlled phase III trial. Lancet Oncol 6:459–468PubMedCrossRefGoogle Scholar
  49. 49.
    Hartung G, Hofheinz RD, Dencausse Y et al (2005) Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: a multicenter randomized phase III study. Onkologie 28:347–350PubMedCrossRefGoogle Scholar
  50. 50.
    Poplin EA, Benedetti JK, Estes NC et al (2005) Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 23:1819–1825PubMedCrossRefGoogle Scholar
  51. 51.
    Smith RE, Colangelo L, Wieand HS et al (2004) Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. J Natl Cancer Inst 96:1128–1132PubMedCrossRefGoogle Scholar
  52. 52.
    Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343–2351PubMedCrossRefGoogle Scholar
  53. 53.
    Labianca R, Fossati R, Zaniboni A et al (2004) Randomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma. J Natl Cancer Inst 96:750–758PubMedGoogle Scholar
  54. 54.
    Quasar Collaborative Group, Gray R, Barnwell J, McConkey C et al (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370:2020–2029PubMedCrossRefGoogle Scholar
  55. 55.
    Lembersky BC, Wieand HS, Petrelli NJ et al (2006) Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 24:2059–2064PubMedCrossRefGoogle Scholar
  56. 56.
    Mamounas E, Wieand S, Wolmark N et al (1999) Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17: 1349–1355PubMedGoogle Scholar
  57. 57.
    Moertel CG, Fleming TR, Macdonald JS et al (1995) Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes’ B2 colon cancer. J Clin Oncol 13:2936–2943PubMedGoogle Scholar
  58. 58.
    (1999) Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol 17:1356–1363Google Scholar
  59. 59.
    O’Connell MJ, Sargent DJ, Windschitl HE et al (2006) Randomized clinical trial of high-dose levamisole combined with 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon cancer. Clin Colorectal Cancer 6:133–139PubMedCrossRefGoogle Scholar
  60. 60.
    Figueredo A, Charette ML, Maroun J et al (2004) Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care’s gastrointestinal cancer disease site group. J Clin Oncol 22:3395–3407PubMedCrossRefGoogle Scholar
  61. 61.
    Benson AB III, Schrag D, Somerfield MR et al (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408–3419PubMedCrossRefGoogle Scholar
  62. 62.
    Compton CC, Fielding LP, Burgart LJ et al (2000) Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:979–994PubMedGoogle Scholar
  63. 63.
    O’Connell MJ, Laurie JA, Kahn M et al (1998) Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16:295–300PubMedGoogle Scholar
  64. 64.
    Haller DG, Catalano PJ, Macdonald JS, Mayer RJ (1998) Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: five-year final report of INT-0089. Prom Am Soc Clin Oncol 17:256aGoogle Scholar
  65. 65.
    Pandor A, Eggington S, Paisley S et al (2006) The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation. Health Technol Assess 10:iii–xiv, 1PubMedGoogle Scholar
  66. 66.
    National Institute for Health and Clinical Excellence (NICE) (2006) Colon cancer (adjuvant): capecitabine & oxaliplatin in the adjuvant treatment of stage III (Dukes’C) colon cancer. NICE, London (Technology Appraisal Guidance; no. 100)Google Scholar
  67. 67.
    (2008) Oxaliplatin 50mg, 100mg powder for intravenous infusion (Eloxatin®). 4/10/05. SMC Report No 211/05. Scottish Medicines Consortium, NHS ScotlandGoogle Scholar
  68. 68.
    de Gramont A, Boni C, Navarro M et al (2007) Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. J Clin Oncol 25[18S]:4007Google Scholar
  69. 69.
    Kuebler JP, Wieand HS, O’Connell MJ et al (2007) Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25:2198–2204PubMedCrossRefGoogle Scholar
  70. 70.
    Twelves CJ (2006) Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness. Clin Colorectal Cancer 6:278–287PubMedCrossRefGoogle Scholar
  71. 71.
    Twelves C, Wong A, Nowacki MP et al (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352:2696–2704PubMedCrossRefGoogle Scholar
  72. 72.
    Schmoll HJ, Cartwright T, Tabernero J et al (2007) Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 25:102–109PubMedCrossRefGoogle Scholar
  73. 73.
    Cassidy J, Douillard JY, Twelves C et al (2006) Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes’ C colon cancer: the X-ACT trial. Br J Cancer 94: 1122–1129PubMedCrossRefGoogle Scholar
  74. 74.
    (2005) Capecitabine 150 and 500 mg tablets (Xeloda®). 08/07/05. Scottish Medicines Consortium, NHS Scotland. Report No.: SMC Report No 193/05Google Scholar
  75. 75.
    Kopec JA, Yothers G, Ganz PA et al (2007) Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. J Clin Oncol 25:424–430PubMedCrossRefGoogle Scholar
  76. 76.
    Watanabe M, Kodaira S, Takahashi T et al (2006) Randomized trial of the efficacy of adjuvant chemotherapy for colon cancer with combination therapy incorporating the oral pyrimidine 1-hexylcarbamoyl-5-fluorouracil. Langenbecks Arch Surg 391:330–337PubMedCrossRefGoogle Scholar
  77. 77.
    Andre T, Quinaux E, Louvet C et al (2007) Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol 25:3732–3738PubMedCrossRefGoogle Scholar
  78. 78.
    Glimelius B, Dahl O, Cedermark B et al (2005) Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncol 44:904–912PubMedGoogle Scholar
  79. 79.
    Wolmark N, Rockette H, Mamounas E et al (1999) Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17:3553–3559PubMedGoogle Scholar
  80. 80.
    Schippinger W, Jagoditsch M, Sorre C et al (2005) A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer. Br J Cancer 92:1655–1662PubMedCrossRefGoogle Scholar
  81. 81.
    Sargent DJ, Wieand HS, Haller DG et al (2005) Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23:8664–8670PubMedCrossRefGoogle Scholar
  82. 82.
    Sobrero A, Frassineti G, Falcone A et al (2005) Adjuvant sequential methotrexate → 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer. Br J Cancer 92:24–29PubMedCrossRefGoogle Scholar
  83. 83.
    Martenson JA Jr, Willett CG, Sargent DJ et al (2004) Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. J Clin Oncol 22:3277–3283PubMedCrossRefGoogle Scholar
  84. 84.
    Arkenau HT, Rettig K, Porschen R (2005) Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion. Int J Colorectal Dis 20:258–261PubMedCrossRefGoogle Scholar
  85. 85.
    Portier G, Elias D, Bouche O et al (2006) Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 24:4976–4982PubMedCrossRefGoogle Scholar
  86. 86.
    Lygidakis NJ, Ziras N, Parissis J (1995) Resection versus resection combined with adjuvant pre- and post-operative chemotherapy-immunotherapy for metastatic colorectal liver cancer. A new look at an old problem. Hepatogastroenterology 42:155–161PubMedGoogle Scholar
  87. 87.
    Asahara T, Kikkawa M, Okajima M et al (1998) Studies of postoperative transarterial infusion chemotherapy for liver metastasis of colorectal carcinoma after hepatectomy. Hepatogastroenterology 45:805–811PubMedGoogle Scholar
  88. 88.
    Lorenz M, Muller HH, Schramm H et al (1998) Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 228:756–762PubMedCrossRefGoogle Scholar
  89. 89.
    Rudroff C, Altendorf-Hoffmann A, Stangl R, Scheele J (1999) Prospective randomised trial on adjuvant hepatic-artery infusion chemotherapy after R0 resection of colorectal liver metastases. Langenbecks Arch Surg 384:243–249PubMedCrossRefGoogle Scholar
  90. 90.
    Kemeny MM, Adak S, Gray B et al (2002) Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy — an intergroup study. J Clin Oncol 20:1499–1505PubMedCrossRefGoogle Scholar
  91. 91.
    Kemeny NE, Niedzwiecki D, Hollis DR et al (2006) Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 24:1395–1403PubMedCrossRefGoogle Scholar
  92. 92.
    Kemeny N, Huang Y, Cohen AM et al (1999) Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 341:2039–2048PubMedCrossRefGoogle Scholar
  93. 93.
    Kemeny NE, Gonen M (2005) Hepatic arterial infusion after liver resection. N Engl J Med 352:734–735PubMedCrossRefGoogle Scholar
  94. 94.
    Garcia-Granero E (2006) [Surgeon-related factors and surgical quality in rectal cancer outcomes. Implications for specialization and organization]. Cir Esp 79:75–77PubMedCrossRefGoogle Scholar
  95. 95.
    Glimelius B, Oliveira J (2008) Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19[Suppl 2]: ii31–ii32PubMedCrossRefGoogle Scholar
  96. 96.
    Berman L, Israel GM, McCarthy SM et al (2007) Utility of magnetic resonance imaging in anorectal disease. World J Gastroenterol 13:3153–3158PubMedGoogle Scholar
  97. 97.
    Videhult P, Smedh K, Lundin P, Kraaz W (2007) Magnetic resonance imaging for preoperative staging of rectal cancer in clinical practice: high accuracy in predicting circumferential margin with clinical benefit. Colorectal Dis 9:412–419PubMedCrossRefGoogle Scholar
  98. 98.
    Karantanas AH, Yarmenitis S, Papanikolaou N, Gourtsoyiannis N (2007) Preoperative imaging staging of rectal cancer. Dig Dis 25:20–32PubMedCrossRefGoogle Scholar
  99. 99.
    Arbman G, Nilsson E, Hallbook O, Sjodahl R (1996) Local recurrence following total mesorectal excision for rectal cancer. Br J Surg 83:375–379PubMedCrossRefGoogle Scholar
  100. 100.
    Enker WE (1997) Total mesorectal excision: the new golden standard of surgery for rectal cancer. Ann Med 29:127–133PubMedGoogle Scholar
  101. 101.
    Heald RJ (1995) Total mesorectal excision is optimal surgery for rectal cancer: a Scandinavian consensus. Br J Surg 82:1297–1299PubMedCrossRefGoogle Scholar
  102. 102.
    Tepper JE, O’Connell MJ, Niedzwiecki D et al (2001) Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol 19:157–163PubMedGoogle Scholar
  103. 103.
    Vironen JH, Halme L, Sainio P et al (2002) New approaches in the management of rectal carcinoma result in reduced local recurrence rate and improved survival. Eur J Surg 168:158–164PubMedCrossRefGoogle Scholar
  104. 104.
    Harling H, Bulow S, Kronborg O et al (2004) Survival of rectal cancer patients in Denmark during 1994–99. Colorectal Dis 6:153–157PubMedCrossRefGoogle Scholar
  105. 105.
    Dahlberg M, Glimelius B, Pahlman L (1999) Changing strategy for rectal cancer is associated with improved outcome. Br J Surg 86:379–384PubMedCrossRefGoogle Scholar
  106. 106.
    Kapiteijn E, Putter H, van de Velde CJ (2002) Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands. Br J Surg 89:1142–1149PubMedCrossRefGoogle Scholar
  107. 107.
    Matthiessen P, Hallbook O, Rutegard J et al (2007) Defunctioning stoma reduces symptomatic anastomotic leakage after low anterior resection of the rectum for cancer: a randomized multicenter trial. Ann Surg 246:207–214PubMedCrossRefGoogle Scholar
  108. 108.
    Harmon JW, Tang DG, Gordon TA et al (1999) Hospital volume can serve as a surrogate for sur geon volume for achieving excellent outcomes in colorectal resection. Ann Surg 230:404–411PubMedCrossRefGoogle Scholar
  109. 109.
    Ritchie WP Jr, Rhodes RS, Biester TW (1999) Work loads and practice patterns of general surgeons in the United States, 1995–1997: a report from the American Board of Surgery. Ann Surg 230:533–542PubMedCrossRefGoogle Scholar
  110. 110.
    Steele RJ (1996) The influence of surgeon case volume on outcome in site-specific cancer surgery. Eur J Surg Oncol 22:211–213PubMedCrossRefGoogle Scholar
  111. 111.
    Phillips RK, Hittinger R, Blesovsky L et al (1984) Local recurrence following’ curative’ surgery for large bowel cancer: I. The overall picture. Br J Surg 71:12–16PubMedCrossRefGoogle Scholar
  112. 112.
    McArdle CS, Hole D (1991) Impact of variability among surgeons on postoperative morbidity and mortality and ultimate survival. BMJ 302:1501–1505PubMedCrossRefGoogle Scholar
  113. 113.
    Hermanek P, Hohenberger W (1996) The importance of volume in colorectal cancer surgery. Eur J Surg Oncol 22:213–215PubMedCrossRefGoogle Scholar
  114. 114.
    Porter GA, Soskolne CL, Yakimets WW, Newman SC (1998) Surgeon-related factors and outcome in rectal cancer. Ann Surg 227:157–167PubMedCrossRefGoogle Scholar
  115. 115.
    Buess G, Kipfmuller K, Ibald R et al (1988) Clinical results of transanal endoscopic microsurgery. Surg Endosc 2:245–250PubMedCrossRefGoogle Scholar
  116. 116.
    Lee W, Lee D, Choi S, Chun H (2003) Transanal endoscopic microsurgery and radical surgery for T1 and T2 rectal cancer. Surg Endosc 17:1283–1287PubMedCrossRefGoogle Scholar
  117. 117.
    Serra A, Bombardo JJ, Mora LL et al (2006) [Transanal endoscopic microsurgery (TEM). Current situation and future expectations]. Cir Esp 80:123–132CrossRefGoogle Scholar
  118. 118.
    del Castillo-Diego J, Puig-La Calle J, Mayol-Martinez JA, Garcia-Aguilar J (2002) Tratamiento local del cáncer de recto. Cir Esp 72:40–44Google Scholar
  119. 119.
    Middleton PF, Sutherland LM, Maddern GJ (2005) Transanal endoscopic microsurgery: a systematic review. Dis Colon Rectum 48:270–284PubMedCrossRefGoogle Scholar
  120. 120.
    Floyd ND, Saclarides TJ (2006) Transanal endoscopic microsurgical resection of pT1 rectal tumors. Dis Colon Rectum 49:164–168PubMedCrossRefGoogle Scholar
  121. 121.
    Maslekar S, Beral DL, White TJ et al (2006) Transanal endoscopic microsurgery: where are we now? Dig Surg 23:12–22PubMedCrossRefGoogle Scholar
  122. 122.
    Hahnloser D, Wolff BG, Larson DW et al (2005) Immediate radical resection after local excision of rectal cancer: an oncologic compromise? Dis Colon Rectum 48:429–437PubMedCrossRefGoogle Scholar
  123. 123.
    Mellgren A, Sirivongs P, Rothenberger DA et al (2000) Is local excision adequate therapy for early rectal cancer? Dis Colon Rectum 43:1064–1071PubMedCrossRefGoogle Scholar
  124. 124.
    Masaki T, Sugiyama M, Atomi Y et al (2001) The indication of local excision for T2 rectal carcinomas. Am J Surg 181:133–137PubMedCrossRefGoogle Scholar
  125. 125.
    Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740PubMedCrossRefGoogle Scholar
  126. 126.
    Bosset JF, Calais G, Mineur L et al (2005) Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results — EORTC 22921. J Clin Oncol 23:5620–5627PubMedCrossRefGoogle Scholar
  127. 127.
    Gerard JP, Conroy T, Bonnetain F et al (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203. J Clin Oncol 24:4620–4625PubMedCrossRefGoogle Scholar
  128. 128.
    Biondo S, Navarro M, Marti-Rague J et al (2005) Response to neoadjuvant therapy for rectal cancer: influence on long-term results. Colorectal Dis 7:472–479PubMedCrossRefGoogle Scholar
  129. 129.
    Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al (2004) Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 72:15–24PubMedCrossRefGoogle Scholar
  130. 130.
    Crane CH, Skibber JM, Feig BW et al (2003) Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma. Cancer 97:517–524PubMedCrossRefGoogle Scholar
  131. 131.
    Willett CG (1996) Organ preservation in anal and rectal cancers. Curr Opin Oncol 8:329–333PubMedCrossRefGoogle Scholar
  132. 132.
    Wagman R, Minsky BD, Cohen AM et al (1998) Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis: long term follow-up. Int J Radiat Oncol Biol Phys 42:51–57PubMedGoogle Scholar
  133. 133.
    Bujko K, Kepka L, Michalski W, Nowacki MP (2006) Does rectal cancer shrinkage induced by preoperative radio(chemo)therapy increase the likelihood of anterior resection? A systematic review of randomised trials. Radiother Oncol 80:4–12PubMedCrossRefGoogle Scholar
  134. 134.
    Colorectal Cancer Collaborative Group (2001) Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet 358:1291–1304CrossRefGoogle Scholar
  135. 135.
    Smalley SR, Benedetti JK, Williamson SK et al (2006) Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol 24:3542–3547PubMedCrossRefGoogle Scholar
  136. 136.
    Chau I, Norman AR, Cunningham D et al (2005) Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer. Eur J Cancer 41:1551–1559PubMedCrossRefGoogle Scholar
  137. 137.
    Tsavaris N, Gennatas K, Kosmas C et al (2004) Leucovorin and fluorouracil vs levamisole and fluorouracil as adjuvant chemotherapy in rectal cancer. Oncol Rep 12:927–932PubMedGoogle Scholar
  138. 138.
    Sakamoto J, Ohashi Y, Hamada C et al (2004) Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol 22:484–492PubMedGoogle Scholar
  139. 139.
    Hyams DM, Mamounas EP, Petrelli N et al (1997) A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Breast and Bowel Project Protocol R-03. Dis Colon Rectum 40:131–139PubMedCrossRefGoogle Scholar
  140. 140.
    Francois Y, Nemoz CJ, Baulieux J et al (1999) Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 17:2396PubMedGoogle Scholar
  141. 141.
    Minsky BD, Cohen AM, Enker WE et al (1997) Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer. Int J Radiat Oncol Biol Phys 37:289–295PubMedGoogle Scholar
  142. 142.
    Videtic GM, Fisher BJ, Perera FE et al (1998) Preoperative radiation with concurrent 5-fluorouracil continuous infusion for locally advanced unresectable rectal cancer. Int J Radiat Oncol Biol Phys 42:319–324PubMedGoogle Scholar
  143. 143.
    Chen ET, Mohiuddin M, Brodovsky H et al (1994) Downstaging of advanced rectal cancer following combined preoperative chemotherapy and high dose radiation. Int J Radiat Oncol Biol Phys 30:169–175PubMedGoogle Scholar
  144. 144.
    Camma C, Giunta M, Fiorica F et al (2000) Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA 284:1008–1015PubMedCrossRefGoogle Scholar
  145. 145.
    O’Connell MJ, Martenson JA, Wieand HS et al (1994) Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331:502–507PubMedCrossRefGoogle Scholar
  146. 146.
    Velenik V, Anderluh F, Oblak I et al (2006) Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial. Croat Med J 47:693–700PubMedGoogle Scholar
  147. 147.
    Collette L, Bosset JF, den Dulk M et al (2007) Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 25:4379–4386PubMedCrossRefGoogle Scholar
  148. 148.
    Rodel C, Liersch T, Hermann RM et al (2007) Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 25:110–117PubMedCrossRefGoogle Scholar
  149. 149.
    Kapiteijn E, Marijnen CA, Nagtegaal ID et al (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638–646PubMedCrossRefGoogle Scholar
  150. 150.
    (1997) Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 336:980–987Google Scholar
  151. 151.
    Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al (2006) Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 93:1215–1223PubMedCrossRefGoogle Scholar
  152. 152.
    Renehan AG, Egger M, Saunders MP, O’Dwyer ST (2002) Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ 324:813PubMedCrossRefGoogle Scholar
  153. 153.
    Nelson H, Petrelli N, Carlin A et al (2001) Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 93:583–596PubMedCrossRefGoogle Scholar
  154. 154.
    Castells A (1998) Anàlisi de l’efectivitat i del cost del control i seguiment dels malalts amb càncer colorectal per a la detecció de recidives curables, 13th edn. Agència d’Avaluació de Tecnologia Mèdica, Barcelona. Servei Català de la Salut. Departament de Sanitat i Seguretat Social. Generalitat de Catalunya, pp 3–4Google Scholar
  155. 155.
    Castells A, Bessa X, Daniels M et al (1998) Value of postoperative surveillance after radical surgery for colorectal cancer: results of a cohort study. Dis Colon Rectum 41:714–723PubMedCrossRefGoogle Scholar
  156. 156.
    Benson AB III, Desch CE, Flynn PJ et al (2000) 2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines. J Clin Oncol 18:3586–3588PubMedGoogle Scholar
  157. 157.
    Desch CE, Benson AB III, Somerfield MR et al (2005) Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 23:8512–8519PubMedCrossRefGoogle Scholar
  158. 158.
    Bengmark S, Hafstrom L (1969) The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. Cancer 23:198–202PubMedCrossRefGoogle Scholar
  159. 159.
    Ohlsson B, Stenram U, Tranberg KG (1998) Resection of colorectal liver metastases: 25-year experience. World J Surg 22:268–276PubMedCrossRefGoogle Scholar
  160. 160.
    Scheele J, Stang R, Altendorf-Hofmann A, Paul M (1995) Resection of colorectal liver metastases. World J Surg 19:59–71PubMedCrossRefGoogle Scholar
  161. 161.
    Jaeck D, Bachellier P, Guiguet M et al (1997) Long-term survival following resection of colorectal hepatic metastases. Association Francaise de Chirurgie. Br J Surg 84:977–980PubMedCrossRefGoogle Scholar
  162. 162.
    Fong Y, Fortner J, Sun RL et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318PubMedCrossRefGoogle Scholar
  163. 163.
    Wagner JS, Adson MA, Van Heerden JA et al (1984) The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg 199:502–508PubMedCrossRefGoogle Scholar
  164. 164.
    Ong KO, Leen E (2007) Radiological staging of colorectal liver metastases. Surg Oncol 16:7–14PubMedCrossRefGoogle Scholar
  165. 165.
    Gobbi PG, Valentino F, Berardi E et al (2008) New insights into the role of age and carcinoembryonic antigen in the prognosis of colorectal cancer. Br J Cancer 98:328–334PubMedCrossRefGoogle Scholar
  166. 166.
    Valls C, Andia E, Sanchez A et al (2001) Hepatic metastases from colorectal cancer: preoperative detection and assessment of resectability with helical CT. Radiology 218:55–60PubMedGoogle Scholar
  167. 167.
    Keogan MT, Edelman RR (2001) Technologic advances in abdominal MR imaging. Radiology 220:310–320PubMedGoogle Scholar
  168. 168.
    Povoski SP, Fong Y, Sgouros SC et al (1998) Role of chest CT in patients with negative chest x-rays referred for hepatic colorectal metastases. Ann Surg Oncol 5:9–15PubMedCrossRefGoogle Scholar
  169. 169.
    Minagawa M, Makuuchi M, Torzilli G et al (2000) Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg 231:487–499PubMedCrossRefGoogle Scholar
  170. 170.
    Nordlinger B, Guiguet M, Vaillant JC et al (1996) Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 77:1254–1262PubMedCrossRefGoogle Scholar
  171. 171.
    Figueras J, Valls C, Rafecas A et al (2001) Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg 88:980–985PubMedCrossRefGoogle Scholar
  172. 172.
    Malik HZ, Gomez D, Wong V et al (2007) Predictors of early disease recurrence following hepatic resection for colorectal cancer metastasis. Eur J Surg Oncol 33:1003–1009PubMedCrossRefGoogle Scholar
  173. 173.
    Figueras J, Burdio F, Ramos E et al (2007) Effect of subcentimeter nonpositive resection margin on hepatic recurrence in patients undergoing hepatectomy for colorectal liver metastases. Evidences from 663 liver resections. Ann Oncol 18:1190–1195PubMedCrossRefGoogle Scholar
  174. 174.
    Simmonds PC, Primrose JN, Colquitt JL et al (2006) Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 94:982–999PubMedCrossRefGoogle Scholar
  175. 175.
    Mentha G, Majno P, Terraz S et al (2007) Treatment strategies for the management of advanced colorectal liver metastases detected synchronously with the primary tumor. Eur J Surg Oncol 33:S76–S83PubMedGoogle Scholar
  176. 176.
    Adam R, Avisar E, Ariche A et al (2001) Fiveyear survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 8:347–353PubMedCrossRefGoogle Scholar
  177. 177.
    Giacchetti S, Itzhaki M, Gruia G et al (1999) Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10:663–669PubMedCrossRefGoogle Scholar
  178. 178.
    Dawson LE, Russell AH, Tong D, Wisbeck WM (1983) Adenocarcinoma of the sigmoid colon: sites of initial dissemination and clinical patterns of recurrence following surgery alone. J Surg Oncol 22:95–99PubMedCrossRefGoogle Scholar
  179. 179.
    Chu DZ, Lang NP, Thompson C et al (1989) Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 63:364–367PubMedCrossRefGoogle Scholar
  180. 180.
    Knorr C, Reingruber B, Meyer T et al (2004) Peritoneal carcinomatosis of colorectal cancer: incidence, prognosis, and treatment modalities. Int J Colorectal Dis 19:181–187PubMedCrossRefGoogle Scholar
  181. 181.
    Sadeghi B, Arvieux C, Glehen O et al (2000) Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 88:358–363PubMedCrossRefGoogle Scholar
  182. 182.
    Jayne DG, Fook S, Loi C, Seow-Choen F (2002) Peritoneal carcinomatosis from colorectal cancer. Br J Surg 89:1545–1550PubMedCrossRefGoogle Scholar
  183. 183.
    Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221:29–42PubMedCrossRefGoogle Scholar
  184. 184.
    Elias D, Sideris L, Pocard M et al (2004) Efficacy of intraperitoneal chemohyperthermia with oxaliplatin in colorectal peritoneal carcinomatosis. Preliminary results in 24 patients. Ann Oncol 15:781–785PubMedCrossRefGoogle Scholar
  185. 185.
    Schneebaum S, Arnold MW, Staubus A et al (1996) Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases. Ann Surg Oncol 3:44–50PubMedCrossRefGoogle Scholar
  186. 186.
    Fujimura T, Yonemura Y, Fujita H et al (1999) Chemohyperthermic peritoneal perfusion for peritoneal dissemination in various intra-abdominal malignancies. Int Surg 84:60–66PubMedGoogle Scholar
  187. 187.
    Sugarbaker H (1999) Succesful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol 43[Suppl]:S15–S25PubMedCrossRefGoogle Scholar
  188. 188.
    Rey Y, Porcheron J, Talabard JN et al (2000) [Peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemohyperthermia]. Ann Chir 125:631–642PubMedCrossRefGoogle Scholar
  189. 189.
    Loggie BW, Fleming RA, McQuellon RP et al (2001) Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am Surg 66:561–568Google Scholar
  190. 190.
    Cavaliere F, Perri P, Di Filippo F et al (2000) Treatment of peritoneal carcinomatosis with intent to cure. J Surg Oncol 74:41–44PubMedCrossRefGoogle Scholar
  191. 191.
    Beaujard AC, Glehen O, Caillot JL et al (2000) Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. Cancer 88:2512–2519PubMedCrossRefGoogle Scholar
  192. 192.
    Witkamp AJ, de Bree E, Kaag MM et al (2001) Extensive cytoreductive surgery followed by intraoperative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer 37:979–984PubMedCrossRefGoogle Scholar
  193. 193.
    Shen P, Levine EA, Hall J et al (2003) Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg 138:26–33PubMedCrossRefGoogle Scholar
  194. 194.
    Verwaal VJ, van Tinteren H, van Ruth S, Zoetmulder FA (2004) Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg 91:739–746PubMedCrossRefGoogle Scholar
  195. 195.
    Verwaal VJ, van Ruth S, Witkamp A et al (2005) Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 12:65–71PubMedCrossRefGoogle Scholar
  196. 196.
    Elias D, Blot F, El Otmany A et al (2001) Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 92:71–76PubMedCrossRefGoogle Scholar
  197. 197.
    Verwaal VJ, van Ruth S, de Bree E et al (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21:3737–3743PubMedCrossRefGoogle Scholar
  198. 198.
    Sugarbaker PH (2005) A curative approach to peritoneal carcinomatosis from colorectal cancer. Semin Oncol 32[Suppl 9]:S68–73PubMedCrossRefGoogle Scholar
  199. 199.
    Elias DM, Pocard M (2003) Treatment and prevention of peritoneal carcinomatosis from colorectal cancer. Surg Oncol Clin N Am 12:543–559PubMedCrossRefGoogle Scholar
  200. 200.
    Verwaal VJ, van Tinteren H, Ruth SV, Zoetmulder FA (2004) Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 85:61–67PubMedCrossRefGoogle Scholar
  201. 201.
    Pocard M, Boige V (2005) [Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal colorectal carcinomatosis: a newly validated standard whose contribution remains to be assessed]. Bull Cancer 92:151–154PubMedGoogle Scholar
  202. 202.
    Esquivel J, Sticca R, Sugarbaker P et al (2007) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol 14:128–133PubMedGoogle Scholar
  203. 203.
    (2006) Guide sur le traitement de la carcinomatose péritonéale par cytoréduction chirurgicale et chimiothérapie hyperthermique intrapéritonéale peropératorie. Comité de l’évolution des pratiques en oncologie (CÉPO), Direction de la lutte contre le cancer (Québec). February. Available at: http://www.msss.gouv.qc.ca/sujets/prob_sante/cancer/download.php?f=cb90cc361eb6b93cadaa67cb4d7 0e6d1
  204. 204.
    National Institute for Clinical Excellence (NICE) Interventional Procedures Programme (2004) Interventional procedures overview of complete cytoreduction and heated intraoperative intraperitoneal chemotherapy (Sugarbaker technique) in patients with peritoneal carcinomatosis. July. Available at: www.nice.org.uk/download.aspx?o=ip256overview

Copyright information

© Feseo 2010

Authors and Affiliations

  • Paula Manchon Walsh
    • 1
    Email author
  • Josep M. Borràs
  • Tàrsila Ferro
  • Josep Alfons Espinàs
  • Colorectal Cancer OncoGuia Group
  1. 1.Department of HealthCatalan Cancer StrategyBarcelonaSpain

Personalised recommendations